Myc-induced MicroRNAs Integrate Myc-mediated Cell Proliferation and Cell Fate

Overview

Journal Cancer Res

Specialty Oncology

Date 2010 Jun 3

PMID 20516112

Citations 29

Authors

Jong Wook Kim

Seiichi Mori

Joseph R Nevins

Affiliations

Soon will be listed here.

Abstract

The Myc pathway, often deregulated in cancer, is critical in determining cell fate by coordinating a gene expression program that links the control of cell proliferation with cell fate decisions. As such, precise control of the Myc pathway activity must be achieved to ensure faithful execution of appropriate cellular response and to prevent progressing toward a malignant state. With recent highlighted roles of microRNAs (miRNA) as critical components of gene control, we sought to evaluate the extent to which miRNAs may contribute in the execution of Myc function. Combined analysis of mRNA and miRNA expression profiles reveals an integration whereby the Myc-mediated induction of miRNAs leads to the repression of various mRNAs encoding tumor suppressors that block cell proliferation including p21, p27, and Rb. In addition, the proapoptotic PTEN tumor suppressor gene is also repressed by Myc-induced miRNAs, suggesting that Myc-induced miRNAs contribute to the precise control of a transcriptional program that coordinates the balance of cell proliferation and cell death.

Citing Articles

MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer.

Doha Z, Wang X, Calistri N, Eng J, Daniel C, Ternes L Nat Commun. 2023; 14(1):5665.

PMID: 37704631 PMC: 10499828. DOI: 10.1038/s41467-023-40841-6.

MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products.

Chan K, Zhang S, Li G, Xu Y, Cui L, Wang Y Aging Dis. 2023; 15(2):640-697.

PMID: 37450923 PMC: 10917530. DOI: 10.14336/AD.2023.0520.

MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Ahmadi S, Rahimi S, Zarandi B, Chegeni R, Safa M J Hematol Oncol. 2021; 14(1):121.

PMID: 34372899 PMC: 8351444. DOI: 10.1186/s13045-021-01111-4.

Identification of an eleven-miRNA signature to predict the prognosis of endometrial cancer.

Lu J, Liang J, Xu M, Wu Z, Cheng W, Wu J Bioengineered. 2021; 12(1):4201-4216.

PMID: 34338136 PMC: 8806668. DOI: 10.1080/21655979.2021.1952051.

Genome-Wide Analysis of c-MYC-Regulated mRNAs and miRNAs and c-MYC DNA-Binding by Next-Generation Sequencing.

Jackstadt R, Kaller M, Menssen A, Hermeking H Methods Mol Biol. 2021; 2318:119-160.

PMID: 34019289 DOI: 10.1007/978-1-0716-1476-1_7.

References

Pelengaris S, Khan M, Evan G . c-MYC: more than just a matter of life and death. Nat Rev Cancer. 2002; 2(10):764-76. DOI: 10.1038/nrc904. View

le Sage C, Nagel R, Egan D, Schrier M, Mesman E, Mangiola A . Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007; 26(15):3699-708. PMC: 1949005. DOI: 10.1038/sj.emboj.7601790. View

Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin G . MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene. 2008; 27(43):5651-61. DOI: 10.1038/onc.2008.178. View

Rodriguez-Viciana P, ULRICH E, Gilbert C, Coffer P, Downward J, Evan G . Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature. 1997; 385(6616):544-8. DOI: 10.1038/385544a0. View

Lu J, Getz G, Miska E, Alvarez-Saavedra E, Lamb J, Peck D . MicroRNA expression profiles classify human cancers. Nature. 2005; 435(7043):834-8. DOI: 10.1038/nature03702. View

Seoane J, Le H, Massague J . Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature. 2002; 419(6908):729-34. DOI: 10.1038/nature01119. View

Di Cristofano A, Pandolfi P . The multiple roles of PTEN in tumor suppression. Cell. 2000; 100(4):387-90. DOI: 10.1016/s0092-8674(00)80674-1. View

Brenner C, Deplus R, Didelot C, Loriot A, Vire E, De Smet C . Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J. 2004; 24(2):336-46. PMC: 545804. DOI: 10.1038/sj.emboj.7600509. View

Smith D, Leone G, DeGregori J, Ahmed M, Qumsiyeh M, Nevins J . Induction of DNA replication in adult rat neurons by deregulation of the retinoblastoma/E2F G1 cell cycle pathway. Cell Growth Differ. 2001; 11(12):625-33. View

10.

Gartel A, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F . Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci U S A. 2001; 98(8):4510-5. PMC: 31865. DOI: 10.1073/pnas.081074898. View

11.

Coller H, Grandori C, Tamayo P, Colbert T, Lander E, Eisenman R . Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A. 2000; 97(7):3260-5. PMC: 16226. DOI: 10.1073/pnas.97.7.3260. View

12.

Schulte J, Horn S, Otto T, Samans B, Heukamp L, Eilers U . MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer. 2007; 122(3):699-704. DOI: 10.1002/ijc.23153. View

13.

Chang T, Zeitels L, Hwang H, Chivukula R, Wentzel E, Dews M . Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A. 2009; 106(9):3384-9. PMC: 2651245. DOI: 10.1073/pnas.0808300106. View

14.

Meyer N, Penn L . Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; 8(12):976-90. DOI: 10.1038/nrc2231. View

15.

Castoldi M, Schmidt S, Benes V, Noerholm M, Kulozik A, Hentze M . A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA). RNA. 2006; 12(5):913-20. PMC: 1440900. DOI: 10.1261/rna.2332406. View

16.

Petrocca F, Vecchione A, Croce C . Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res. 2008; 68(20):8191-4. DOI: 10.1158/0008-5472.CAN-08-1768. View

17.

Mori S, Chang J, Andrechek E, Matsumura N, Baba T, Yao G . Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene. 2009; 28(31):2796-805. PMC: 3008357. DOI: 10.1038/onc.2009.139. View

18.

Bild A, Yao G, Chang J, Wang Q, Potti A, Chasse D . Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2005; 439(7074):353-7. DOI: 10.1038/nature04296. View

19.

Xiao C, Srinivasan L, Calado D, Patterson H, Zhang B, Wang J . Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008; 9(4):405-14. PMC: 2533767. DOI: 10.1038/ni1575. View

20.

Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V . MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007; 14(3):791-8. DOI: 10.1677/ERC-07-0129. View